Replimune Group (NASDAQ:REPL) Issues Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Replimune Group (NASDAQ:REPL) announced its quarterly earnings data on Monday. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.03), FiscalAI reports.

Replimune Group Stock Performance

REPL opened at $11.63 on Monday. Replimune Group has a 52 week low of $1.50 and a 52 week high of $13.24. The company has a quick ratio of 5.60, a current ratio of 5.60 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $960.32 million, a P/E ratio of -3.38 and a beta of 0.88. The stock’s fifty day moving average is $6.23 and its two-hundred day moving average is $7.28.

Analyst Ratings Changes

A number of research firms recently commented on REPL. Wall Street Zen raised Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. BMO Capital Markets cut shares of Replimune Group from a “market perform” rating to an “underperform” rating in a research note on Monday, April 13th. JPMorgan Chase & Co. upgraded shares of Replimune Group from a “neutral” rating to an “overweight” rating and set a $17.00 price target on the stock in a research note on Friday. Wedbush increased their price objective on shares of Replimune Group from $2.00 to $6.00 and gave the company a “neutral” rating in a report on Monday, June 1st. Finally, Piper Sandler cut Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 target price on the stock. in a report on Friday, April 10th. One analyst has rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average price target of $6.00.

Insider Buying and Selling at Replimune Group

In related news, insider Christopher Sarchi sold 12,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $9.24, for a total transaction of $110,880.00. Following the sale, the insider owned 180,962 shares of the company’s stock, valued at $1,672,088.88. This trade represents a 6.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. lifted its stake in shares of Replimune Group by 3,638.9% during the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock worth $33,000 after buying an additional 7,569 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of Replimune Group by 99.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock worth $58,000 after acquiring an additional 6,873 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Replimune Group during the 2nd quarter valued at about $69,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Replimune Group during the 3rd quarter valued at about $85,000. Finally, Tower Research Capital LLC TRC increased its stake in shares of Replimune Group by 2,020.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,692 shares of the company’s stock valued at $90,000 after purchasing an additional 9,235 shares in the last quarter. 92.53% of the stock is owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.